Pin Wang, PhD

Professor

Image of Pin Wang, PhD
Is this your profile? Click to edit

Overview

The Wang laboratory focuses on an emerging field of “immunobioengineering” with the aim of employing engineering tools and principles to quantitatively understand the immune system in health and disease and to develop novel molecular and cellular immunotherapies by precisely modulating disease-specific immune responses. The ongoing research research projects include: 1) exploring various strategies to engineer virus-derived vector systems for dendritic cell-targeted vaccine delivery and oncolytic virus-based immunotherapy; 2) designing and optimizing cellular immunotherapy that is based on molecular engineering of chimeric antigen receptors (CARs); 3) exploring immune cells as drug carriers for targeted delivery of immunomodulatory drugs to enhance cancer immunotherapy; 4) exploring systems biology tools for modeling and understanding details of signaling pathways mediated by designer molecules such as chimeric antigen receptors to activate T cells; 5) developing engineering methods to improve adeno-associated virus (AAV)-based gene delivery. In this research laboratory, bioengineers collaborate with chemists, immunologists, computer scientists, and system biologists to directly address problems in translational immunology and develop and optimize innovative approaches to improve lives of patients suffering from cancer and infectious diseases.

Research Funding

  • In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
    NIH · R01EB017206 · Sep 1, 2013 – Aug 31, 2020 · Role: Co-Principal Investigator
  • SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)
    NIH · R01CA170820 · Sep 17, 2012 – Jun 30, 2017 · Role: Co-Principal Investigator
  • Targeting lentiviruses to infect chosen cells
    NIH · R01AI068978 · Feb 1, 2006 – Jan 31, 2012 · Role: Principal Investigator

Research Keywords

  • Cancer Immunotherapy
  • Immunoengineering
  • T Cell Engineering
  • Chimeric Antigen Receptor
  • Cancer Vaccine
  • Gene Therapy
  • Immuno-Oncology

Publications

  • Visualization of targeted transduction by engineered lentiviral vectors. Gene Ther. 2008 Oct; 15(20):1384-96.. View in PubMed
  • Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008 Mar; 26(3):326-34.. View in PubMed
  • Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A. 2006 Aug 01; 103(31):11479-84.. View in PubMed
  • [Effects of lasix on intraocular pressure]. Nihon Ganka Kiyo. 1967 Mar; 18(3):326-8.. View in PubMed